Initial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program

Price, Alex; Schiff, Joshua; Laugeman, Eric; Maraghechi, B.; Schmidt, Matthew C.; Zhu, Tong; Reynoso, Francisco J.; Hao, Yaowu; Kim, Sang Woo; Morris, Eric D.; Zhao, Xiaodong; Hugo, Geoff; Vlacich, Gregory; DeSelm, Carl J.; Samson, Pamela; Baumann, Brian C.; Badiyan, Shahed N.; Robinson, Clifford G.; Kim, Hyun; Henke, Lauren E.

doi:10.1016/j.ctro.2023.100661

Clinical and Translational Radiation Oncology

2023

DOI: 10.1016/j.ctro.2023.100661

|View full text |Cite

Initial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program

Alex Price

Joshua Schiff

Eric Laugeman

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Function-preserving high-dose adaptive radiotherapy for renal pelvic cancer in a solitary functioning kidney with severe dysfunction: A case report

Hama,

Tate

2024

Ukr. J. Nephrol. Dial.

View full text Add to dashboard Cite

It is challenging to treat renal pelvic cancer in a monofunctioning kidney and severe renal dysfunction while preserving renal function. A 78-year-old man with renal pelvic cancer and G4 chronic kidney disease was treated with high-dose adaptive radiotherapy using helical tomotherapy with a total dose of 74 Gy in 37 fractions. His serum creatinine level before radiotherapy was 2.15 mg/dl, which temporarily increased to 5.00 mg/dl at 9 months after radiotherapy, but gradually decreased to 2.05 mg/dl 2 years later with medical treatment. Follow-up MRI showed complete tumor regression 5.5 years after radiotherapy, and dialysis was avoided. High-dose adaptive radiotherapy may be a viable option for a monofunctioning kidney and severe renal dysfunction complicated by renal pelvic cancer.

show abstract

Function-preserving high-dose adaptive radiotherapy for renal pelvic cancer in a solitary functioning kidney with severe dysfunction: A case report

Hama,

Tate

2024

Ukr. J. Nephrol. Dial.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Initial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program

Cited by 1 publication

References 45 publications

Function-preserving high-dose adaptive radiotherapy for renal pelvic cancer in a solitary functioning kidney with severe dysfunction: A case report

Function-preserving high-dose adaptive radiotherapy for renal pelvic cancer in a solitary functioning kidney with severe dysfunction: A case report

Contact Info

Product

Resources

About